sorafenib has been researched along with adenosine in 8 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (adenosine) | Trials (adenosine) | Recent Studies (post-2010) (adenosine) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 32,536 | 1,075 | 8,930 |
| Protein | Taxonomy | sorafenib (IC50) | adenosine (IC50) |
|---|---|---|---|
| high affinity choline transporter 1 isoform a | Homo sapiens (human) | 0.3851 | |
| Sodium/nucleoside cotransporter 1 | Homo sapiens (human) | 5.5 | |
| Sodium/nucleoside cotransporter 2 | Homo sapiens (human) | 5.5 | |
| Adenosine receptor A3 | Homo sapiens (human) | 0.0011 | |
| Adenosine receptor A1 | Homo sapiens (human) | 0.0023 | |
| Equilibrative nucleoside transporter 1 | Homo sapiens (human) | 63 | |
| Solute carrier family 28 member 3 | Homo sapiens (human) | 3.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 4 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ide, M; Kamikawa, T; Kashiwagi, H; Matsuo, A; Miura, T; Morikami, K; Muraoka, T; Nishihara, M | 1 |
| Bar-Yehuda, S; Benjaminov, O; Ciuraru, NB; Cohen, S; Farbstein, M; Fishman, P; Fishman, S; Harpaz, Z; Kerns, WD; Medalia, G; Patoka, R; Silverman, MH; Singer, B; Stemmer, SM | 1 |
| Hsiao, HH; Liu, TP; Lo, HL; Wei, LS; Yang, PM | 1 |
| Alseth, I; Aukrust, P; Berges, N; Bjørås, M; Dahl, TB; Fladeby, C; Gregersen, I; Halvorsen, B; Holm, S; Klungland, A; Kong, XY; Nawaz, MS; Quiles-Jiménez, A; Segers, F; Suganthan, R; Vågbø, C; Vik, ES | 1 |
| Bu, X; Chen, D; Chen, L; Chen, X; Cheng, C; He, W; Liang, H; Lin, Z; Niu, Y; Sun, L; Wan, A; Wan, G; Zhan, S; Zhang, X | 1 |
| Cai, X; Cen, D; Gorshkov, K; Ji, L; Jiang, S; Liang, X; Lin, Z; Mao, Q; Tang, M; Wan, Z; Xia, S; Xu, J; Zheng, J | 1 |
| Jiang, H; Lv, W; Ning, G; Wang, Y | 1 |
1 review(s) available for sorafenib and adenosine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for sorafenib and adenosine
| Article | Year |
|---|---|
CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.
Topics: Adenosine; Adult; Aged; Apoptosis; Carcinoma, Hepatocellular; Child; Female; Humans; Leukocytes, Mononuclear; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Purinergic P1 Receptor Agonists; Receptor, Adenosine A3; Sorafenib; Wnt Signaling Pathway | 2013 |
6 other study(ies) available for sorafenib and adenosine
| Article | Year |
|---|---|
Identification of a selective inhibitor of transforming growth factor β-activated kinase 1 by biosensor-based screening of focused libraries.
Topics: Biosensing Techniques; Humans; Kinetics; MAP Kinase Kinase Kinases; Protein Kinase Inhibitors; Surface Plasmon Resonance | 2017 |
S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells.
Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Cell Survival; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Gene Knockdown Techniques; Hep G2 Cells; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Humans; Indazoles; Niacinamide; Phenylurea Compounds; Polycomb Repressive Complex 2; Pyridones; S-Adenosylmethionine; Sorafenib | 2015 |
Deletion of Endonuclease V suppresses chemically induced hepatocellular carcinoma.
Topics: Adenosine; Animals; Antineoplastic Agents; Carcinogenesis; Cell Line; Deoxyribonuclease (Pyrimidine Dimer); Gene Expression; Humans; Inosine; Liver; Liver Neoplasms, Experimental; Mice, Knockout; RNA Editing; RNA, Transfer; Sequence Analysis, RNA; Sorafenib | 2020 |
RNA m
Topics: Adenosine; Animals; Autophagy; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Forkhead Box Protein O3; HEK293 Cells; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Male; Methylation; Methyltransferases; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; RNA, Messenger; RNA, Neoplasm; Sorafenib | 2020 |
N
Topics: Adenosine; Animals; Antineoplastic Agents; Apoptosis; beta Catenin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; RNA, Circular; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Identification of an m6A-Related Signature as Biomarker for Hepatocellular Carcinoma Prognosis and Correlates with Sorafenib and Anti-PD-1 Immunotherapy Treatment Response.
Topics: Adenosine; Biomarkers, Tumor; Carcinoma, Hepatocellular; Databases, Genetic; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Male; Neoplasm Staging; Prognosis; Sorafenib; Treatment Outcome | 2021 |